A new US Food and Drug Administration guidance on recommendations for demonstrating that injector products will reliably deliver the drug component on an emergency basis could help head off recalls and shortages of injectors that fail to perform as expected in the postmarket setting.
Injectors used to administer drugs on a one-time, emergency basis should be demonstrated to have a “remote probability” of failure...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?